Objectives: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by increased platelet destruction and altered production. Despite the well-described pathophysiological background of immune dysregulation, current treatment guidelines consist of monotherapy with different drugs, with no tool to predict which patient is more suitable for each therapeutic modality.
Methods: In our study, we attempted to determine differences in the immune setting, comparing the patients' responses to administered therapy. During 12-month follow-up, we assessed blood count, antiplatelet autoantibodies, and T lymphocyte subsets in peripheral blood in 35 patients with ITP (newly diagnosed or relapsed disease).
Results: Our data show that the value of antiplatelet autoantibodies, the percentage of cytotoxic T lymphocytes, and the immunoregulatory index (IRI, CD4+ / CD8+ T cell ratio) differ significantly by treatment response. Responders have a higher IRI (median 2.1 vs. 1.5 in non-responders, = 0.04), higher antiplatelet autoantibodies (median 58 vs. 20% in non-responders, = 0.01) and lower relative CD8+ T cells count ( = 0.02) before treatment.
Discussion: The results suggest that immunological parameters (antiplatelet autoantibodies, relative CD8+ T cell count and IRI) could be used as prognostic tools for a worse clinical outcome in patients with ITP.
Conclusion: These biomarkers could be utilized for stratification and eventually selection of treatment preferring combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/16078454.2024.2304486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis.
Thromb Res
January 2025
Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy. Electronic address:
Article Synopsis
- Anti-Phospholipid Antibodies (aPL) increase the risk of blood clots, and the effectiveness of antiplatelet drugs for preventing these clots in aPL carriers was evaluated through a systematic review of existing studies.
- The review included 1056 participants and found that low-dose acetylsalicylic acid (LDA) significantly reduced both arterial and venous thrombotic events compared to control groups without increasing major bleeding risks.
- However, the safety and benefit of LDA may vary depending on the specific aPL profile of the individuals, which remains uncertain.
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia.
Thromb Res
December 2024
Jiangsu Institute of Hematology, Cyrus Tang Medical Institute, The First Affiliated Hospital Collaborative Innovation Center of Hematology, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, National Clinical Research Center for Hematological Diseases, Suzhou, China. Electronic address:
Introduction: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts. ITP patients with anti-platelet glycoprotein (GP) Ibα (a subunit of GPIb-IX-V complex) autoantibodies, which induce Fc-independent signaling and platelet clearance, are refractory to conventional treatment. Protein kinase C (PKC) is activated by the binding of the ligand von Willebrand factor (VWF) to GPIbα and regulates VWF-GPIbα-induced platelet activation.
View Article and Find Full Text PDFImmune Thrombocytopenia: Immune Dysregulation and Genetic Perturbations Deciphering the Fate of Platelets.
Front Biosci (Landmark Ed)
September 2024
Department of Oncology, Kazakh-Russian Medical University, 050004 Almaty, Kazakhstan.
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder. It involves impaired production and excessive destruction of platelets. It is a complex and heterogeneous disorder with unknown pathophysiology.
View Article and Find Full Text PDFDengue Envelope Protein as a Cytotoxic Factor Inducing Hemorrhage and Endothelial Cell Death in Mice.
Int J Mol Sci
October 2024
Department of Molecular Biology and Human Genetics, Tzu-Chi University, Hualien 970, Taiwan.
Dengue virus (DENV) infection, prevalent in tropical and subtropical regions, can progress to dengue hemorrhagic fever (DHF), which increases mortality during secondary infections. DHF is characterized by endothelial damage and vascular leakage. Despite its severity, no specific antiviral treatments exist, and the viral factors responsible for endothelial damage remain unclear.
View Article and Find Full Text PDFDancing with disorder: chorea - an unusual and neglected manifestation of antiphospholipid syndrome.
Lupus Sci Med
October 2024
Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Article Synopsis
- Chorea, a rare neurological issue related to antiphospholipid syndrome (APS), involves involuntary movements, with unclear clinical features; this study examines the evidence of chorea associated with antiphospholipid antibodies (aPL).
- The research included 180 patients, mostly women around 22.8 years old, revealing that most had chorea as their first symptom and often experienced it as a single episode, with notable laboratory findings including high positivity rates for various aPL tests.
- Treatment varied widely but led to improvement in 95.5% of patients, highlighting that chorea, while significant, is often not recognized as a symptom of APS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!